Benjamin Burnett, analyst at Stifel Nicolaus, reiterates coverage on Mirati Therapeutics (MRTX) in the Healthcare sector with a Buy rating. TipRanks.com has Burnett rated as a 2.5 star analyst with a 4% return on investment and a 32% success rate. Burnett has set a price target of $202.00 .
TipRanks.com reports that MRTX currently has 10 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $215.78 . The target pricing ranges from a high forecast of $300.00 down to a low forecast of $173.00 .
MRTX’s last closing price was $167.10 which would put the average price target at 29.13% upside.
In addition, TradingView issued a Buy rating for MRTX over the next month.
Remember, securities are volatile, so please do your own research on MRTX.
Other analysts covering MRTX include:
- Yigal Nochomovitz of Citigroup issued a buy rate with the price target of $244 on September 21st
- Jay Olsen of oppenheimer issued a hold with the price target of $175 on September 20th
- Edward White of H C Wainwright issued a buy rate with the price target of $247 on September 20th
- Maury Raycroft of Jefferies issued a buy rate with the price target of $193 on September 19th
If you are interest in stocks like MRTX or stocks in the Healthcare sector, please click here.
TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
When an MRTX analyst reiterates coverage on stocks, we will let you know. Please make sure you subscribe to our email newsletter to get timely alerts. Join thousands of other investors, you can always unsubscribe.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data.
Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.